Oscar Health CEO Bertolini sells $35.7 million in company stock
Oscar Health CEO Mark T Bertolini sold over $35.7 million worth of company stock across several transactions on June 29 and June 30, 2026, to cover tax withholding obligations from vested performance stock units. The sales involved a total of 1,238,996 shares of Class A Common Stock, with prices ranging from $28.35 to $30.08 per share. Despite the sales, Bertolini still holds 7,751,570 shares, while the stock has seen a 98% surge in the past six months and is considered slightly overvalued by InvestingPro.
Oscar Health CEO Bertolini sells $35.7 million in company stock By Investing.com
Oscar Health CEO Mark T Bertolini sold approximately $35.7 million worth of company stock through multiple transactions on June 29 and June 30, 2026. These sales, conducted to cover tax withholding obligations from vested performance stock units, involved 1,238,996 shares at weighted average prices between $28.35 and $30.08. Following these transactions, Bertolini retains direct ownership of 7,751,570 shares, while the company's stock has shown significant recent growth and positive analyst upgrades.
Oscar Health CEO Bertolini sells $35.7 million in company stock By Investing.com
Oscar Health CEO Mark T Bertolini sold approximately $35.7 million worth of company stock through several transactions on June 29 and June 30, 2026. These sales, executed to cover tax withholding obligations from vested performance stock units, involved 1,238,996 shares of Class A Common Stock. Following these transactions, Bertolini still directly holds over 7.7 million shares, amidst recent analyst upgrades and strategic company developments.
Tax-driven Oscar Health (OSCR) CEO sale of 1.24M shares under 10b5-1
Oscar Health CEO Mark T. Bertolini sold 1,238,996 shares of Class A Common Stock between June 29-30, 2026, generating approximately $35.77 million. These sales were reportedly made to cover tax withholding obligations related to vested performance stock units and were executed under a pre-arranged Rule 10b5-1 plan. Following these transactions, Bertolini still directly holds 7,751,570 shares, indicating a tax-driven liquidation rather than a change in investment outlook.
Oscar Health director Mario Schlosser sells $30.18m in stock
Oscar Health director Mario Schlosser sold Class A common stock worth approximately $30.18 million on June 23, 2026, through a Rule 10b5-1 trading plan. The sales involved both direct holdings and shares held indirectly via family trusts, following his acquisition of shares through Class B common stock conversion and option exercises. These transactions occurred amidst Oscar Health's volatile stock performance and recent analyst upgrades, and a transition in Mr. Schlosser's role within the company.
Form 4 Oscar Health Inc For: 30 June By Investing.com
This article announces the filing of Form 4 for Oscar Health Inc. for the period ending June 30. It is a brief corporate notice published by Investing.com. The content itself does not provide details of the Form 4 filing but serves as an announcement for its availability.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock
Oscar Health CEO Mark Bertolini sold over 1.2 million shares of Class A Common Stock for approximately $34.9 million on June 25 and 26, 2026. These sales were primarily to cover tax obligations related to vested performance and restricted stock units and were conducted under a Rule 10b5-1 trading plan. Despite the sale, Bertolini still directly holds nearly 9 million shares, and the company has recently seen positive analyst upgrades and strategic changes.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock
Oscar Health CEO Mark Bertolini sold over $34.9 million worth of Class A Common Stock across multiple transactions on June 25 and June 26, 2026. These sales were conducted to cover tax withholding obligations related to vested performance and restricted stock units, under a pre-established Rule 10b5-1 trading plan. Despite the sale, Bertolini still holds a significant number of shares, and analysts expect the health insurance company to become profitable this year, with several recent upgrades to its stock rating.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock
Oscar Health CEO Mark T. Bertolini sold approximately $34.9 million worth of company stock across June 25 and June 26, 2026, to cover tax withholding obligations from vested performance and restricted stock units. This sale, executed under a Rule 10b5-1 trading plan, occurred near the stock's 52-week high after shares surged 105% in six months. Following the transactions, Bertolini retains 8,990,566 shares, as the health insurance company, valued at $8.8 billion, anticipates profitability this year.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock By Investing.com
Oscar Health CEO Mark T. Bertolini sold over $34.9 million in company stock across multiple transactions on June 25 and June 26, 2026. The sales were conducted to cover tax obligations related to vested performance and restricted stock units, under a pre-established trading plan. Following these sales, Bertolini still directly holds nearly 9 million shares, and the company, valued at $8.8 billion, is anticipated to become profitable this year.
Oscar Health (OSCR) CEO Mark Bertolini sells 1.2M shares for tax obligations
Oscar Health CEO Mark T. Bertolini sold 1,206,310 shares of Class A common stock for approximately $34.91 million on June 25-26, 2026. These sales were pre-planned under a Rule 10b5-1 instruction letter and were conducted to satisfy tax withholding obligations related to vested performance and restricted stock units. Following these transactions, Bertolini retains a significant stake, holding at least 8,990,566 shares of Class A common stock.
Oscar Health director Mario Schlosser sells $30.18m in stock By Investing.com
Oscar Health director Mario Schlosser sold over $30 million worth of Class A Common Stock on June 23, 2026, through both direct and indirect sales under a Rule 10b5-1 trading plan. Despite the significant sale near the stock's 52-week high, the company's shares had recently surged by 95%, with InvestingPro analysis suggesting they remain slightly undervalued. Schlosser also acquired a similar number of shares through the conversion of Class B Common Stock, and the company has seen recent upgrades from analysts and changes in his executive role.
Oscar Health (NYSE: OSCR) director sells shares after large option exercise
Oscar Health director Mario Schlosser sold 1,027,500 Class A common shares across several family dynasty trusts and his direct holdings. Concurrently, he exercised a stock option for 660,000 Class B shares at $9.75 and converted other Class B shares, acquiring a total of 2,347,500 shares via derivatives. These transactions were executed under a Rule 10b5-1 trading plan adopted on March 24, 2026.
Form 4 Oscar Health Inc For: 25 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Oscar Health Inc. on June 25. Form 4 filings disclose changes in beneficial ownership of a company's securities, often indicating insider transactions. The article provides the title and source but no further details about the specific contents of the Form 4.
Oscar Health director Mario Schlosser sells $30.18m in stock
Oscar Health director Mario Schlosser sold 1,026,500 shares of Class A Common Stock for approximately $30.18 million on June 23, 2026, executed via a Rule 10b5-1 trading plan. Despite the sale occurring near the stock's 52-week high and a 95% surge over six months, InvestingPro suggests the stock remains slightly undervalued. Concurrently, Schlosser acquired 1,027,500 shares through conversion of Class B stock, while recent analyst upgrades and strategic adjustments, including his transition to an advisor role, have marked other notable developments for Oscar Health.
Form 4 Oscar Health Inc For: 25 June By Investing.com
This article reports on a Form 4 filing by Oscar Health Inc. for June 25, 2026. It mentions the company's stock symbol OSCR, which saw a 3.91% increase. The content is brief and primarily serves as an announcement for the financial filing.
Oscar Health, Inc. Class A Actuals & Estimates (NYSE:OSCR)
This article provides an overview of Oscar Health, Inc. (NYSE: OSCR) stock performance, forecasts, and key financial data. It highlights recent stock price movements, analyst price targets ranging from $13.00 to $35.00, and historical highs and lows. The content also delves into recent earnings, revenue figures, market capitalization, and upcoming earnings dates for OSCR.
Oscar Health director Mario Schlosser sells $30.18m in stock By Investing.com
Oscar Health director Mario Schlosser sold over $30.18 million worth of Class A Common Stock on June 23, 2026, through direct sales and family trusts. These transactions occurred after a significant 95% surge in Oscar Health's shares, near their 52-week high, yet InvestingPro analysis suggests the stock remains slightly undervalued. Schlosser also acquired 1,027,500 shares through the conversion of Class B Common Stock, and the sale was executed under a Rule 10b5-1 trading plan.
Form 4 Oscar Health Inc For: 25 June By Investing.com
This article announces the filing of a Form 4 for Oscar Health Inc. on June 25th. Form 4s disclose transactions made by company insiders, but the article does not provide specific details about the transactions. It suggests that readers might find more detailed information within the Investing.com platform.
Oscar Health director Mario Schlosser sells $30.18m in stock By Investing.com
Oscar Health director Mario Schlosser sold approximately $30.18 million worth of the company's Class A Common Stock on June 23, 2026. The sales were conducted through a Rule 10b5-1 trading plan and occurred as the stock neared its 52-week high after a significant rally. Despite the sale, InvestingPro analysis suggests the stock remains slightly undervalued, and recent analyst upgrades further highlight the company's positive trajectory.
Why (OSCR) Price Action Is Critical for Tactical Trading
This article analyzes Oscar Health Inc. Class A (NASDAQ: OSCR) stock performance, highlighting that if near and mid-term strong sentiment holds, it could extend to the long term. It identifies compelling upside potential due to the absence of resistance levels above the current price. The analysis includes institutional trading strategies, multi-timeframe signal analysis, and AI-generated signals for traders.
Oscar Health shareholders back board, pay and auditor
Oscar Health shareholders recently approved the election of eight directors, the compensation for named executive officers, and the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026. This indicates strong support for the current board, executive pay practices, and financial oversight. An analyst rating suggests a "Hold" with a $30 price target, while TipRanks' AI Analyst, Spark, rates OSCR as "Outperform" due to improving financial quality and technical momentum.
Oscar Health, Inc. (OSCR) Stock Declines While Market Improves: Some Information for Investors
Oscar Health, Inc. (OSCR) stock declined by 2.25% in a recent trading session, underperforming the broader market despite a strong monthly gain of 24.88%. Investors are anticipating the company's upcoming earnings report, with expectations of significant EPS and revenue growth year-over-year. The stock currently holds a Zacks Rank #3 (Hold) and has a Forward P/E ratio of 61.51, which is a premium compared to its industry.
Oscar Health shareholders back board, pay and auditor
Oscar Health shareholders re-elected all eight directors, approved executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor at their 2026 Annual Meeting. This indicates strong support for the current leadership, pay practices, and financial oversight. An AI analyst from TipRanks rates OSCR as an "Outperform" due to improving financial quality and technical momentum.
Oscar Health (NYSE: OSCR) 2026 vote backs directors, pay and auditor
Oscar Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected eight directors to serve until the 2027 Annual Meeting. They also approved the compensation of named executive officers in an advisory vote and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026. The meeting achieved a quorum with over 820 million votes represented, reflecting strong shareholder participation and support for the proposals.
Director at Oscar Health (NYSE: OSCR) awarded 8,475 RSUs
Oscar Health director Laura W. Lang was granted 8,475 restricted stock units (RSUs) of Class A common stock at no cash cost. These RSUs vest on the earlier of one year from the grant date or the next annual stockholder meeting, contingent on continued service. Following this award, Lang's direct holdings in Oscar Health total 82,840 shares.
Director Vanessa Wittman receives 8,475 RSUs at Oscar Health (OSCR)
Oscar Health director Vanessa Ames Wittman was granted 8,475 restricted stock units (RSUs) as equity compensation, as reported in a Form 4 filing. The RSUs vest within a year or by the next annual meeting and will be settled in Class A shares after specific conditions are met. Following this transaction, Wittman directly holds 137,121 shares of Oscar Health Class A common stock, including these new RSUs.
Oscar Health (OSCR) director receives 8,475 RSUs, updates share holdings
Oscar Health director Sid Sankaran has been granted 8,475 restricted stock units (RSUs) of Class A common stock, increasing his direct holdings to 22,609 shares. These RSUs vest on the earlier of one year from the grant date or the next annual stockholder meeting, contingent on his continued service. Additionally, 795,686 shares are held indirectly by Victoria Family LLC, for which Sankaran disclaims beneficial ownership except for his pecuniary interest.
Director David Plouffe granted 8,475 RSUs at Oscar Health (OSCR)
Oscar Health director David Plouffe was granted 8,475 restricted stock units (RSUs) of the company's Class A common stock. These RSUs, which vest on the earlier of one year or the next annual stockholders' meeting subject to continued service, increase his direct holdings to 137,121 shares. The grant is valued at $0.00 per share and will be settled in Class A shares upon specific events after vesting.
Director William Gassen receives 8,475 RSU award at Oscar Health (NYSE: OSCR)
Oscar Health director William Gassen received an award of 8,475 restricted stock units (RSUs) as part of his director compensation, not an open-market purchase. These RSUs have no cash exercise price and will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, provided he remains in service. Following this grant, Gassen directly holds 82,840 shares in the company.
Oscar Health, Inc. Files 8-K Regulation FD Disclosure with SEC – Company Information and Filing Details (June 8, 2026)
Oscar Health, Inc. filed an 8-K Regulation FD Disclosure on June 8, 2026, confirming its participation in the Goldman Sachs 47th Annual Global Healthcare Conference and reaffirming full-year 2026 guidance. The company's presentation will be webcast live, and investors are cautioned about forward-looking statements and encouraged to review risk factors. This filing signals confidence in its business trajectory without disclosing new material events.
Oscar Health, Inc. Class A Trade Ideas — XETR:9VY
This article compiles various trade ideas and analyses for Oscar Health, Inc. Class A (XETR:9VY, NYSE:OSCR) from multiple contributors on TradingView. It covers both bullish and bearish perspectives, discussing factors like potential impacts of Trump's policies, Q1 results, technical indicators, and analyst price targets. While some analysts project significant upside due to Oscar's tech-driven model and growth potential, others caution about volatility, rising healthcare costs, and overbought conditions.
Book value per share of Oscar Health, Inc. Class A – XETR:9VY
This article displays the book value per share for Oscar Health, Inc. Class A (XETR:9VY). It provides financial data and indicates that the market is currently closed without any trades. The page is sourced from TradingView, with market data from ICE Data Services and reference data from FactSet.
Understanding Momentum Shifts in (OSCR)
This article analyzes Oscar Health Inc. (OSCR) using AI models to identify momentum shifts and provide trading strategies. It highlights divergent sentiment readings, suggesting choppiness, and offers specific long, breakout, and short strategies with entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for near-term, mid-term, and long-term horizons.
Oscar Health CAO Victoria Baltrus sells $33,416 in shares By Investing.com
Oscar Health's Chief Accounting Officer, Victoria Baltrus, sold 1,523 shares of Class A Common Stock for $33,416 to cover tax withholding obligations. This sale occurred under a Rule 10b5-1 trading plan and leaves her with 214,589 shares. The insider transaction follows a weekly stock decline of 8.2%, yet the company reported a strong Q1 2026 earnings beat and received an upgrade from Wells Fargo.
Oscar Health CAO Victoria Baltrus sells $33,416 in shares
Oscar Health's Chief Accounting Officer, Victoria Baltrus, sold 1,523 shares of Class A Common Stock for a total of $33,416. These sales, conducted under a Rule 10b5-1 trading plan, were primarily to cover tax withholding obligations. Following these transactions, Ms. Baltrus still directly holds 214,589 shares.
Oscar Health (OSCR) CFO’s planned share sale covers equity tax withholding
Oscar Health's CFO, Richard Scott Blackley, sold 31,683 shares of Class A Common Stock on June 2, 2026, as reported in a Form 4 filing. These sales, executed under a Rule 10b5-1 instruction letter dated August 8, 2025, were primarily to cover tax withholding obligations associated with the vesting of previously granted equity awards. This indicates a routine, pre-planned compensation-related liquidity event rather than a discretionary sale based on a change in market outlook for OSCR.
Oscar Health CAO Victoria Baltrus sells $33,416 in shares
Oscar Health's Chief Accounting Officer, Victoria Baltrus, sold 1,523 shares of the company's Class A Common Stock for $33,416 to cover tax obligations from vested equity awards. This transaction occurred on June 2, 2026, and leaves Ms. Baltrus with 214,589 shares. The sale follows a weekly stock decline of 8.2%, despite a 43% year-to-date increase, and coincided with Oscar Health reporting strong Q1 2026 earnings and a rating upgrade from Wells Fargo.
Oscar Health (OSCR) CAO sells 1,523 shares in tax-driven 10b5-1 trades
Oscar Health's Chief Accounting Officer, Victoria Baltrus, sold 1,523 shares of Class A common stock on June 2, 2026, in two open-market transactions. These sales, executed under a Rule 10b5-1 instruction letter, were primarily to cover tax withholding obligations from previously vested equity awards. After these transactions, Baltrus still retains a significant holding of approximately 214,589 shares, indicating the sale was largely tax-related and not a discretionary reduction in ownership.
Oscar Health (OSCR) director sells 34,120 shares under Rule 10b5-1 plan
Oscar Health director Mario Schlosser sold a total of 34,120 shares of Class A common stock on June 2, 2026, in two open-market transactions, according to a Form 4 filing. These sales, executed under a Rule 10b5-1 plan established on August 8, 2025, were primarily to cover tax withholding obligations arising from vested equity awards. The shares were sold at weighted average prices of $22.45 and $21.74, totaling approximately $748,633.
Oscar Health (OSCR) legal chief sells 9,859 shares under 10b5-1 plan
Oscar Health's Chief Legal Officer, Adam McAnaney, sold 9,859 shares of Class A common stock in two open-market transactions on June 2, 2026. These sales, executed under a pre-arranged Rule 10b5-1 plan established on August 8, 2025, were primarily to cover tax withholding obligations related to vested equity awards. The shares were sold at weighted average prices of approximately $22.45 and $21.74, with individual trades occurring within specified price ranges.
Oscar Health (NYSE: OSCR) president sells 12,475 shares under Rule 10b5-1 plan
Janet Liang, President of Oscar Insurance, a subsidiary of Oscar Health (NYSE: OSCR), sold 12,475 shares of Class A common stock on June 2, 2026. The sales, totaling approximately $273,716, were made under a pre-arranged Rule 10b5-1 plan established in August 2025 to cover tax withholding obligations from vesting equity awards. Following these transactions, Liang retains 262,592 shares, including those to be issued from restricted stock units.
Oscar Health, Inc. Class A Trade Ideas — MUN:9VY
This article compiles various trade ideas and analyses for Oscar Health, Inc. (MUN:9VY, NYSE:OSCR) from multiple traders. The analyses present both bullish and some cautious outlooks, with several traders projecting significant upside potential for the stock in 2025 and beyond due to its innovative business model, improving financials, and strong analyst price targets. While some pinpoint specific entry and exit points, others offer long-term investment perspectives, acknowledging some short-term volatility or overbought conditions.
Oscar Health Announces Strong Financial Results for First Quarter 2026 And Reaffirms 2026 Guidance
Oscar Health (NYSE: OSCR) reported strong financial results for the first quarter of 2026, with total revenue reaching $4.6 billion and a significant increase in net income to $679.0 million. The company reaffirmed its full-year 2026 guidance, highlighting improvements in its medical loss ratio and SG&A expense ratio due to disciplined pricing, cost management, and increased membership. CEO Mark Bertolini emphasized Oscar Health's continued progress towards profitability and its focus on a consumer-driven health economy.
Oscar Health, Inc. Class A Trade Ideas — HAM:9VY
This article compiles various trade ideas and analyses for Oscar Health, Inc. Class A (HAM:9VY, NYSE:OSCR) from multiple traders on TradingView. The common themes include the company's impressive growth, potential for breakouts, and its innovative approach to health insurance, despite some concerns about low margins and market volatility. Many analysts suggest significant upside potential, with some identifying specific price targets and technical indicators, while others advise caution due to political risks and high valuation.
Oscar Health Announces Strong Financial Results for First Quarter 2026 And Reaffirms 2026 Guidance
Oscar Health, Inc. announced strong financial results for the first quarter ended March 31, 2026, including a significant increase in total revenue to approximately $4.6 billion against $3.0 billion in Q1 2025, and net income of $679.0 million. The company reported a lower medical loss ratio and a higher Adjusted EBITDA, reflecting improved operating performance. Oscar Health also reaffirmed its full-year 2026 guidance, driven by increased membership and disciplined pricing strategies.
Oscar Health CFO Richard Blackley sells $2.75m in common stock
Oscar Health CFO Richard Blackley sold 110,000 shares of Class A common stock for over $2.75 million on May 18, 2026, through a Rule 10b5-1 trading plan. Despite the sale, he still directly holds over 1.1 million shares. The company's stock is trading near its 52-week high after an 88% surge, and analysts project profitability this year following a strong earnings beat in Q1 2026.
Oscar Health CFO Richard Blackley sells $2.75m in common stock
Oscar Health CFO Richard Blackley sold 110,000 shares of Class A common stock for $2.75 million on May 18, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while Oscar Health shares are near their 52-week high, following an 88% surge in six months. Analysts predict the company will turn profitable this year with projected earnings of $1.20 per share, a significant improvement from a recent loss.
CFO’s 110,000-share Oscar Health (NYSE: OSCR) sale is pre-planned
Oscar Health's CFO, Richard Scott Blackley, sold 110,000 shares of Class A Common Stock for $25.03 per share, totaling $2.75 million. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Blackley directly holds 1,106,660 shares, with an additional 75,000 shares held indirectly by the MQB Irrevocable Trust.
Oscar Health CFO Richard Blackley sells $2.75m in common stock
Oscar Health CFO Richard Blackley sold 110,000 shares of Class A common stock for over $2.75 million on May 18, 2026, through a pre-arranged trading plan. Despite Oscar Health remaining unprofitable in the last year, analysts project profitability for the current year, with shares trading near a 52-week high after an 88% surge. Blackley still directly holds over 1.1 million shares.
